When can I stop dual antiplatelet therapy in patients with drug-eluting stents?

Cleveland Clinic journal of medicine

Sushil Allen Luis, MBBS, FRACP^4¹  Juan Simon Rico-Mesa, MD^1²  Megha Prasad, MD^3³  Carlos Uribe, MD, FACC, FSCAI^2⁴ 

[1]Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN^4

[2]Department of Medicine, University of Texas Health, San Antonio, TX, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN^1

[3]Division of Cardiology, Columbia University Medical Center, New York, NY^3

[4]Interventional Cardiologist, Associate Professor of Medicine, CES University, Program director of Interventional Cardiology, UPB University, Clinica CardioVID, Hospital Pablo Tobon Uribe, Medellin, Colombia^2

DOI  :  

学科分类：卫生学

来源: Cleveland Clinic Educational Foundation

【 摘 要 】

Stopping dual antiplatelet therapy (DAPT) (eg, clopidogrel plus aspirin) after 3 months is reasonable in patients with stable ischemic heart disease who have a second-generation drug-eluting stent and a high bleeding risk, with stable ischemic disease defined as at least 1 year free of acute coronary syndromes. However, these patients should continue lifelong aspirin monotherapy. Current guidelines suggest that in stable ischemic disease, the risk-benefit ratio may favor an even shorter duration of DAPT than the 6 months currently recommended. 1

【 授权许可】

CC BY